Helixmith Co., Ltd

KOSDAQ 084990.KQ

Helixmith Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2023: USD 87.53 M

Helixmith Co., Ltd Cash and Short-Term Investments is USD 87.53 M for the year ending December 31, 2023, a 81.42% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Helixmith Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2022 was USD 48.25 M, a -9.91% change year over year.
  • Helixmith Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2021 was USD 53.56 M, a -82.34% change year over year.
  • Helixmith Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2020 was USD 303.29 M, a 96.85% change year over year.
  • Helixmith Co., Ltd Cash and Short-Term Investments for the year ending December 31, 2019 was USD 154.07 M, a 244.40% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
KOSDAQ: 084990.KQ

Helixmith Co., Ltd

CEO Mr. Sunyoung Kim D.Phil., Ph.D.
IPO Date Dec. 29, 2005
Location South Korea
Headquarters Building 203
Employees 132
Sector Healthcare
Industries
Description

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.

Similar companies

086900.KQ

Medy-Tox Inc.

USD 77.77

-3.69%

000100.KS

Yuhan Corporation

USD 83.97

-5.00%

128940.KS

Hanmi Pharm. Co., Ltd.

USD 159.35

-4.24%

095700.KQ

Genexine, Inc.

USD 3.04

-3.81%

069620.KS

Daewoong pharmaceutical Co.,Ltd

USD 89.76

-4.42%

StockViz Staff

February 4, 2025

Any question? Send us an email